Core Viewpoint - Galmed Pharmaceuticals Ltd. has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission, highlighting its focus on developing Aramchol for liver diseases and expanding its product pipeline [1][2]. Company Overview - Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in therapeutics for liver, cardiometabolic diseases, and gastrointestinal oncology [1][3]. - The company is primarily focused on the development of Aramchol, targeting its use in combination therapy for non-alcoholic steatohepatitis (NASH) and exploring its potential for oncological indications [3]. Product Development Strategy - The company is actively pursuing opportunities to expand and diversify its product pipeline, specifically targeting cardiometabolic indications and other innovative drug candidates that align with its expertise in drug development [3].

Core Insights - KULR Technology Group, Inc. reported a significant year of progress in 2025, focusing on battery safety and next-generation energy infrastructure, with a strategic shift towards a product-led model [2][10] Financial Results Fourth Quarter 2025 - Revenues decreased by 15% to $2,863,961 compared to $3,370,594 in Q4 2024 [2] - SG&A expenses increased by 77% to $7,860,094 from $4,437,032 in the same period last year [3] - R&D expenses rose to $3,545,372 from $1,246,161 in Q4 2024 [3] - Operating loss was $15,367,084, compared to $3,540,864 in Q4 2024 [3] - Net loss increased to $44,261,358, or $0.97 per share, from a net loss of $4,620,461, or $0.16 per share in Q4 2024, primarily due to a $28,256,664 mark-to-market loss on bitcoin holdings [4] Full-Year 2025 - Revenues increased by 51% to $16,170,404 from $10,737,481 in 2024, reflecting strong relationship building with energy, transport, and aerospace partners [5] - SG&A expenses rose to $27,696,969 from $15,979,852 in 2024, attributed to strategic investments [6] - R&D expenses increased by 127% to $10,755,036 from $4,738,305 in 2024, driven by planned increases in services and personnel [7] - Operating loss for the year was $43,000,505, compared to $15,234,959 in 2024 [8] - Net loss for 2025 was $61,899,782, or $1.56 per share, compared to a net loss of $17,523,629, or $0.75 per share in 2024 [8] Cash Position - As of December 31, 2025, the company reported cash balances of $13,300,188, down from $29,831,858 in 2024 [9] - Bitcoin holdings increased to $93,995,256 from $20,281,184 in 2024 [9]

Core Insights - NIKE, Inc. reported third quarter fiscal 2026 results with revenues of $11.3 billion, flat on a reported basis and down 3 percent on a currency-neutral basis [4][5][48] - The company emphasized ongoing efforts to enhance business health and quality, with a focus on profitable long-term growth [2][4] - Net income decreased by 35 percent to $0.5 billion, with diluted earnings per share also down 35 percent to $0.35 [11][17][48] Financial Performance - Revenues for NIKE Brand were $11.0 billion, up 1 percent on a reported basis but down 2 percent on a currency-neutral basis, primarily affected by declines in EMEA and Greater China [5][38] - Wholesale revenues increased to $6.5 billion, up 5 percent on a reported basis and up 1 percent on a currency-neutral basis, mainly driven by growth in North America [4][5] - NIKE Direct revenues were $4.5 billion, down 4 percent on a reported basis and down 7 percent on a currency-neutral basis, attributed to a 9 percent decrease in NIKE Brand Digital [5][11] Expense and Margin Analysis - Selling and administrative expenses rose by 2 percent to $4.0 billion [3][14] - Gross margin decreased by 130 basis points to 40.2 percent [4][13] - Demand creation expenses remained flat at $1.1 billion, while operating overhead expenses increased by 3 percent to $2.9 billion [11][14] Shareholder Returns - The company returned approximately $609 million to shareholders through dividends, marking a 3 percent increase from the previous year [6][48] - NIKE has maintained a strong track record with 24 consecutive years of increasing dividend payouts [6] Balance Sheet Overview - Cash and equivalents and short-term investments totaled $8.1 billion, down approximately $2.3 billion due to cash dividends, bond repayments, capital expenditures, and share repurchases [11] - Inventories were reported at $7.5 billion, down 1 percent, reflecting a decrease in units and product mix shifts [11][19]

Core Insights - PVH Corp. reported strong fourth quarter results for 2025, exceeding guidance in revenue, operating margin, and EPS on a non-GAAP basis, driven by its brands Calvin Klein and TOMMY HILFIGER [2][3] - The company anticipates continued growth in 2026, with a focus on direct-to-consumer (DTC) channels and positive wholesale order books in Europe [2][3] - Despite challenges from tariffs and a fluctuating macroeconomic environment, PVH expects stable operating margins and slight revenue growth for 2026 [3][5] Financial Performance - Fourth quarter revenue reached $2.505 billion, a 6% increase compared to the prior year, while full year revenue was $8.950 billion, up 3% [3][10] - The fourth quarter operating margin was 9.9% on a GAAP basis and 10.0% on a non-GAAP basis, exceeding guidance of approximately 9% [3][10] - Full year operating margin was 2.6% on a GAAP basis and 8.8% on a non-GAAP basis, also exceeding guidance [3][10] 2026 Outlook - Revenue for 2026 is projected to increase slightly compared to 2025, with operating margins expected to remain stable at approximately 8.8% on a non-GAAP basis [3][5] - EPS for 2026 is projected to be in the range of $11.80 to $12.10 on a non-GAAP basis, reflecting a net negative impact from tariffs [5][16] - The company plans to repurchase at least $300 million in stock in 2026, following $560 million in repurchases completed in 2025 [3][13] Regional Performance - EMEA revenue increased by 8% in the fourth quarter, while Americas revenue grew by 4%, driven by wholesale business growth [8][11] - APAC revenue was flat compared to the prior year, impacted by the timing of Lunar New Year [8][11] - Licensing revenue increased by 10% in the fourth quarter, primarily due to non-recurring contractual royalties [8][11] Tariff Impact - The company faced a negative impact of approximately 170 basis points from tariffs in the fourth quarter and 80 basis points for the full year [3][10] - For 2026, a projected gross impact of approximately $195 million to EBIT is expected due to tariffs, equating to about $3.30 per share [14][18]

Core Insights - Ameresco has announced key executive appointments aimed at driving growth and enhancing operational efficiency, with Nicole Bulgarino and Lou Maltezos named as Co-Presidents, and Peter Christakis appointed as Chief Operating Officer [1][2][4] Leadership Changes - Effective April 1, 2026, Nicole Bulgarino and Lou Maltezos will serve as Co-Presidents, working alongside George Sakellaris, who remains CEO and Chairman [2] - Nicole will focus on data centers and large energy infrastructure projects, while Lou will oversee the non-Federal project organization and continue leading Smart Building Solutions and Ameresco Canada [2] Strategic Direction - The leadership changes reflect a commitment to leadership continuity and succession planning, positioning Ameresco to capture market opportunities through a unified strategy and clear accountability [3] - The new structure aims to optimize resource deployment and strengthen operational alignment, fostering collaboration and a shared culture within the company [3] Operational Focus - Peter Christakis, as COO, will ensure consistency in project execution and risk management, while overseeing critical functions such as Procurement, Health & Safety, U.S. solar and battery operations, and European operations [4] - The appointments are seen as a step forward in building the capabilities necessary for future growth, emphasizing the strength of internal talent [5]

Core Insights - Nanobiotix provided an operational update and financial results for the year ended December 31, 2025, highlighting advancements in its clinical programs and financial position [1][6]. Operational Highlights - The global development program for JNJ-1900 (NBTXR3) is progressing as planned, targeting significant markets in oncology, particularly in head and neck and lung cancers [3]. - Clinical results across various tumor types, including esophageal, pancreatic, melanoma, head and neck, and lung cancers, support the broad potential of JNJ-1900 [3]. - The company strengthened its financial position through a non-dilutive royalty financing of up to €71 million and an amendment to the licensing agreement for JNJ-1900 [3]. - Cash runway extended into early 2028 with €52.8 million in cash and cash equivalents as of December 31, 2025 [3][12]. Financial Results - Revenues for the year ended December 31, 2025, were €32.6 million, a significant increase from a negative €7.2 million in 2024, primarily due to a one-off positive revenue recognition impact [8]. - Research and Development (R&D) expenses decreased by 43% to €23.1 million, reflecting the removal of funding obligations for the NANORAY-312 study [9]. - Selling, General and Administrative (SG&A) expenses were €20.4 million, a slight decrease from €20.5 million in 2024 [10]. - The net loss attributable to shareholders was €24.0 million, or €0.50 per share, a 65% decrease from €68.1 million, or €1.44 per share, in 2024 [11]. Future Outlook - The company anticipates that its cash and cash equivalents will support operations into early 2028, contingent on receiving the remaining $21 million from HealthCare Royalty [13]. - Nanobiotix is positioned for continued growth with upcoming clinical data readouts expected in 2026 from various studies [3][5].

Core Viewpoint - The E.W. Scripps Company has successfully completed the sale of its ABC-affiliated station WRTV in Indianapolis for $83 million, following the sale of its Fox-affiliated station WFTX in Fort Myers for $40 million, generating a total of $123 million in cash proceeds to be used for debt reduction and acquisition of ION-affiliated stations [1][2]. Group 1: Recent Transactions - The sale of WRTV to Circle City Broadcasting was finalized for $83 million [1]. - The sale of WFTX to Sun Broadcasting was completed for $40 million, contributing to a total cash inflow of $123 million from both transactions [2]. - The aggregate purchase price for the INYO stations, which Scripps plans to acquire, is approximately $54 million, pending the timing of the deal closure [3]. Group 2: Strategic Implications - The proceeds from the sales will be utilized for debt paydown and to facilitate the purchase of 23 ION-affiliated stations, which were divested to comply with FCC ownership rules [2][3]. - Ownership of the INYO stations is expected to be immediately accretive to Scripps Networks division segment profit and margin, enhancing coordination with other Scripps stations for new local programming opportunities [3]. - Scripps has also entered into an agreement to swap stations in five markets with Gray Television, aimed at strengthening its competitive position in key Mountain West markets, pending regulatory approval [4].

Core Viewpoint - AZZ Inc. will review its financial results for the fourth quarter and fiscal year 2026 on April 23, 2026, with a press release to be issued after market close on April 22, 2026 [1]. Group 1: Financial Results Announcement - The conference call to discuss the financial results will take place at 11:00 a.m. ET on April 23, 2026 [1]. - Interested parties can access the conference call via specific phone numbers or through a webcast on the Company's Investor Relations page [2]. Group 2: Company Overview - AZZ Inc. is recognized as the leading independent provider of hot-dip galvanizing and coil coating solutions, serving a wide range of end-markets [3]. - The company's business segments offer sustainable metal coating solutions that enhance the longevity and appearance of essential infrastructure and products [3].

Core Viewpoint - Newmont Corporation will release its first quarter 2026 results on April 23, 2026, followed by a conference call to discuss the results [1][2] Company Overview - Newmont is the world's leading gold company and also produces copper, zinc, lead, and silver, with operations in favorable mining jurisdictions across Africa, Australia, Latin America, North America, and Papua New Guinea [3] - The company is the only gold producer listed in the S&P 500 Index and is recognized for its strong environmental, social, and governance practices [3] - Founded in 1921, Newmont has been publicly traded since 1925 and is known for its value creation through robust safety standards and technical expertise [3] Upcoming Events - A conference call to discuss the first quarter 2026 results will take place at 5:30 PM Eastern Daylight Time on April 23, 2026, with a replay available on the company's website [1][2]

Core Insights - Edible Garden AG Incorporated is strategically evolving from its core controlled environment agriculture (CEA) platform into a broader consumer packaged goods (CPG) business, focusing on higher-margin opportunities [5][7][20] - The company is expanding its distribution network and product offerings, particularly in the ready-to-drink (RTD) category, which is projected to grow significantly in the coming years [7][20] Financial & Operating Highlights - For the three months ended December 31, 2025, revenue was approximately $4.1 million, a slight increase from $3.9 million in the same period in 2024, supported by new account launches [9] - The cost of goods sold for the same period was approximately $5.3 million, up from $3.8 million in 2024, primarily due to onboarding new customers during a peak season [10] - Gross profit for the quarter was approximately $(1.2) million, compared to $0.0 million in 2024, reflecting a gross margin of approximately -29% [11] - Selling, general and administrative expenses increased to approximately $4.6 million for the quarter, up from $2.6 million in 2024, driven by investments in personnel and infrastructure [12] Year-End Financial Overview - For the year ended December 31, 2025, revenue was approximately $12.8 million, down from $13.9 million in 2024, due to a strategic shift away from lower-margin products [13] - The cost of goods sold for the year was $13.0 million, an increase of 12.7% from $11.5 million in 2024, driven by elevated procurement and logistics costs [14] - Gross profit for the year was $(0.2) million, a decrease of $2.5 million from $2.3 million in 2024, with a gross margin decline to (1.6%) from 16.7% [15] - Selling, general and administrative expenses rose by 34.6% to $15.6 million for the year, compared to $11.6 million in 2024, with significant contributions from depreciation, rent, and professional fees [16] Strategic Initiatives - The company is focusing on expanding into the RTD category, leveraging its sustainable manufacturing infrastructure and established retail relationships [7][20] - A strategic partnership with Tetra Pak is planned to enhance processing capabilities for RTD products, aiming to meet growing consumer demand for clean-label nutrition [7] - The global RTD market is valued at approximately $842.5 billion in 2025 and is projected to reach roughly $1.26 trillion by 2033, presenting a significant growth opportunity for the company [7]